Transport Pharmaceuticals, Inc., a Mack Molding customer and leader in combination drug/medical devices for the topical treatment of dermatological conditions, has been awarded the 2007 Frost & Sullivan North American Technology Innovation of the Year Award. Transport was selected for the award because of its significant contributions in enhancing the delivery of topically applied dermatologic drugs.
Transport’s lead product, the SoloVir™ Electrokinetic Transdermal System (SoloVir™ ETS), may represent a significant breakthrough in the treatment of herpes labialis, also known as cold sores. SoloVir™ ETS enables the delivery of the company’s novel five-percent acyclovir gel formulation by means of electric current via a small, finger mounted, microprocessor-driven control unit with a single-use, unit-dose drug cartridge. This innovative design allows patients to safely self-administer the drug, exactly where and when it is needed.
“I am pleased to accept this award on behalf of Transport and recognize the team that makes our unique drug/device combination products a reality,” said Dennis Goldberg, Ph.D., president & CEO of Transport. “It’s not just management and investors; it’s the engineers, chemists, biologists, clinical development, regulatory and quality assurance experts who have contributed to our continued success.”
Mack manufactures and tests the device for clinical trials and FDA submission. Mack also supports a clinical trial evaluation process for disassembling and collecting data on returned product.
Based on strong clinical results from a recently completed Phase 2 study, Transport will advance SoloVir™ ETS into its next clinical stage in 2008.
Transport is a Massachusetts-based, privately held specialty pharmaceutical company. For more information, please visit www.transportpharma.com.
Contact: Joan Magrath, VP, Sales & Engineering